STAT+：美国卫生与公众服务部将允许药房配制某些未经批准的肽类产品
摘要
华盛顿——美国卫生与公众服务部（HHS）发布了一项政策，将暂时允许配制药店生产某些肽类产品，从而增加人们获得这些被“让美国再次健康”运动中的许多人所推崇的实验性健康疗法的机会。该政策声明，HHS将运用“执法裁量权”，不对州持照药房、联邦机构或持照医生配制此前得到美国食品药品监督管理局（FDA）咨询委员会支持的六种肽类产品采取行动。这项提议发布之际，FDA仍在权衡是否允许配制药店生产肽类产品。今年7月，FDA的一个咨询委员会投票建议，允许这些药店获准生产其中六种物质。继续阅读STAT+以获取更多内容。
English
WASHINGTON — The Department of Health and Human Services released a policy that will temporarily allow compounding pharmacies to manufacture some peptide products, increasing access to the experimental wellness therapies embraced by many in the Make America Healthy Again movement. The policy states that HHS will use “enforcement discretion” to not take action against state-licensed pharmacies, federal facilities, or licensed physicians compounding six peptides previously backed by a Food and Drug Administration advisory committee. The proposal comes as the FDA continues to weigh whether to allow compounding pharmacies to manufacture peptides. In July, an FDA advisory panel voted to recommend that these pharmacies be cleared to manufacture six of these substances . Continue to STAT+ to read